“To understand the symptoms and signs of sinus thrombosis, two different mechanisms should be distinguished: thrombosis of the cerebral veins, with local effects caused by venous obstruction, and thrombosis of the major sinuses…, which causes intracranial hypertension. In the majority of patients, these two processes occur simultaneously.”
“CVT presents with a remarkably wide spectrum of signs and modes of onset, thus mimicking numerous other disorders. The most common symptoms and signs are headache, seizures, focal neurological deficits, altered consciousness, and papilloedema, which can present in isolation or in association with other symptoms.”
“… the cause of the sudden deterioration was as a result of the continuing extension of the thrombotic process with secondary haemorrhage, seizures and a further rise in intracranial pressure, which then led to cerebral herniation (“coning”).”
“… there is intracranial bleeding … [the] cause [of which] is thrombosis (clotting) of the veins draining from the deep part of the brain, namely this affects the straight sinus and the deep veins draining the brain. The sagittal sinus also shows evidence of thrombosis. This has resulted in venous infarction and haemorrhage in both basal ganglia, with swelling, secondary subarachnoid haemorrhage and intraventricular haemorrhage.”
“The CT brain scan performed on08/10/2002 shows evidence of established thrombosis of the deep cerebral venous structures with characteristic features of infarction of the deep grey matter structures, subarachnoid and intraventricular haemorrhage and brain swelling. In addition there was evidence of coning ....”
“The CT scan taken at 01.20 hours on8 October 2002 shows evidence of cerebral venous thrombosis affecting the deep venous system of the brain and there is evidence of haemorrhagic infarction typical of venous infarction in the thalami, basal ganglia and secondary subarachnoid and intraventricular haemorrhage.”
“The neuroradiologists agreed that on the morning of 7 October a CT scan would have shown features of a significant increase in raised intracranial pressure with brain swelling and evidence of CVST, i.e. thrombosis of cerebral veins. It is not known in which area of the cerebral venous system [Mrs] Carter's thrombosis began, i.e. in the more superficial or in the more deep venous structures. Therefore it is not possible to identify the location of the CVST at this stage.”
“…furthermore, a cause cannot be found in about 15% of cases, the individual outcome may still be difficult to predict, and the disorder may occasionally worsen despite anticoagulation.”
“CVT is now typically recognised as a non-septic disorder with various clinical presentations and a usually favourable outcome, with mortality well below 10%.” (Emphasis added)
“Over the last 19 years as a consultant neurologist with regular responsibility for the acute neurology service for a population of 3 million, I have seen many patients with CVST. These are typically tragic cases like Mrs Carter: young women, many of whom are in the later stages of pregnancy or the early stages of the perium. Since the early 1990s it has been my routine practice to anticoagulate these patients. In my recollection most have survived and done well but others have progressed and died despite anticoagulation.”
“A meta-analysis of these two trials showed that the use of [anticoagulation] led to an absolute risk reduction in death or dependency of 13% (confidence interval -30 to +3%) with a relative risk reduction of 54%. Although this difference did not reach statistical significance both trials showed a consistent and clinicably meaningful trend in favour of [anticoagulation] and demonstrated the safety of anticoagulant therapy. Thus, data from controlled trials favoured the use of [anticoagulation] in patients with CVST because it may reduce the risk of fatal outcome and severe disability and does not promote [intracranial haemorrhage] at least in the small number of patients in the trials.”
“…the two available randomised trials…show that with Heparin there is an absolute reduction in mortality of 14% and in death or dependency of 15%, with relative risk reductions of 70% and 56%, respectively. I maintain that although these differences do not quite reach statistical significance (because the numbers are too small), they are highly meaningful from a clinical stand point. Indeed, the risk reductions are of far greater magnitude than those reported for aspirin, which has been recommended in the acute treatment of arterial stroke.”